Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Buy to ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Daina ...

Gilead Sciences (NASDAQ:GILD) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead ...

STAT+ subscribers can sign up here to get it delivered to their inbox. The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...